Erste Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Erste Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-33,500	Closed	-$169K	–	804
2025 Q2	$169K	Hold	33,500	–	–	﹤0.01%	778
2025 Q1	$195K	Hold	33,500	–	–	﹤0.01%	472
2024 Q4	$248K	Hold	33,500	–	–	﹤0.01%	479
2024 Q3	$234K	Hold	33,500	–	–	﹤0.01%	476
2024 Q2	$254K	Hold	33,500	–	–	﹤0.01%	464
2024 Q1	$341K	Hold	33,500	–	–	﹤0.01%	453
2023 Q4	$355K	Hold	33,500	–	–	0.01%	450
2023 Q3	$260K	Hold	33,500	–	–	﹤0.01%	464
2023 Q2	$247K	Hold	33,500	–	–	﹤0.01%	474
2023 Q1	$216K	Hold	33,500	–	–	﹤0.01%	484
2022 Q4	$257K	Hold	33,500	–	–	0.01%	474
2022 Q3	$360K	Hold	33,500	–	–	0.01%	454
2022 Q2	$270K	Hold	33,500	–	–	0.01%	487
2022 Q1	$239K	Buy	+33,500	New	+$356K	﹤0.01%	495

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Erste Asset Management's RXRX Position: Q3 2025 in Review

Erste Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 33,500 shares — an estimated $169K sold.

Erste Asset Management first reported a position in RXRX in Q1 2022 and held it in 14 quarters. The position peaked at $360K in Q3 2022. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

Erste Asset Management reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Erste Asset Management sold 33,500 Recursion Pharmaceuticals shares in Q3 2025, an estimated $169K.
Erste Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 14 quarters.
Erste Asset Management's Recursion Pharmaceuticals position peaked at $360K in Q3 2022.
322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Erste Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.